The fifth batch of national procurement reports: 60 varieties are involved, more than half of the injections!

Medical Network, April 16 News On April 15, the "Notice on Reporting the Purchasing Data of the Fifth Batch of National Organizations for Centralized Procurement of Drugs" circulated in the industry, which means that the fifth batch of national procurement officially kicked off.

 

According to the report volume catalogue, this time involves 60 varieties and as many as 207 product specifications.
It is by far the largest scale and the largest number of products, including omega-3 fish oil medium/long-chain fat emulsion injection, A Facalcitol oral constant-release dosage form, aripiprazole oral constant-release dosage form, azithromycin injection, esomeprazole (esomeprazole) injection, cefuroxime injection and other clinically commonly used varieties, as well as budi Three inhalants of acetonide, compound ipratropium bromide and ipratropium bromide, and special dosage forms such as moxifloxacin eye drops.
Some insiders predict that the market size that affects the terminal may exceed 50 billion yuan.

 

Injection up to 31 varieties , more than half

 

Injections have always been the main force in the hospital market.
According to data from Minai.
com, the sales of terminal chemical injections in China's public medical institutions reached 636.
9 billion yuan in 2019.
It can be found from the circulated fifth batch of reports that the focus of national centralized procurement is gradually tilting towards injections.
Among the 60 varieties involved in the reporting list, 31 are injections, azithromycin injection, cisatracurium besilate injection, iohexol injection, iodixanol injection, fluconazole sodium chloride injection, method Sudil injection, glycopyrrolate injection, cefuroxime injection and many other commonly used clinical injections are listed.

 

Taking the included esomeprazole sodium as an example, Minnet data shows that in 2019, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal treatment of peptic ulcer The size of the drug market exceeded 40 billion yuan, and the proportions of injection and oral administration were 58% and 42% respectively.
From the perspective of injection products, pantoprazole sodium for injection, esomeprazole sodium for injection (esomeprazole sodium), and lansoprazole for injection ranked in the top five.

 

　　Among them, the sales of esomeprazole sodium in 2019 exceeded 3 billion yuan, and the market share of the leading company AstraZeneca in the first half of 2020 was close to 50%.
Domestic pharmaceutical companies Zhongzhengda Tianqing Pharmaceutical Group and Jiangsu Osaikang Pharmaceutical The industry accounts for 29% and 13% respectively.
The price competition of related pharmaceutical companies may cause another change in the market competition pattern.

 

　　With the formal implementation of the injection consistency evaluation policy last year, the time for the over-evaluated injections to be included in the national procurement has been significantly shortened.
According to data analysis, as of the end of March, there are as many as 33 injection varieties that meet the requirements of the fifth batch of centralized procurement (original research + number of reviewers ≥ 3).
Compared with the pre-incorporated varieties, the National Medical Insurance Bureau should collect all of them.
The goal of mining is accelerating.

 

　　In the fourth batch of national centralized procurement, 8 injections including pantoprazole, ambroxol, and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 31 injections, the intensity of the price competition can be imagined.
After sorting out, it is found that the more competitive varieties include: rivaroxaban tablets with 13 over-rated companies, esomeprazole sodium for injection over-rated by 9 companies, and ofloxacin chlorinated with over-rated 6 companies Sodium injection, 5 reviewed ceftriaxone sodium for injection, ceftazidime for injection, etc.

 

　　April 19 or officially start reporting

 

　　According to the requirements of the document, the fifth batch of national-organized centralized drug pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement product range related procurement data will rely on the national-organized centralized drug procurement comprehensive service platform, and take the form of online reporting.

 

　　According to the arrangement, local medical insurance bureaus will guide and coordinate procurement agencies to complete the reporting work: before 24:00 on April 18, all provinces can conduct volume reporting operation tests through the system; volume reporting will be officially launched on April 19, and each province will select medical institutions directly or on behalf of the provincial newspaper reported that way, complete the relevant medicines pre-purchase amount, its Chinese medicine treatment direct reporting agency must be completed before at 4:00 on April 2 on the 30th; and in front at 17:00 on May 12, the provinces need to complete the pre-related drugs Procurement volume review work, summarized, exported and printed, stamped with the official seal of the Provincial Medical Insurance Bureau, and submitted the electronic files and scanned copies to the Joint Procurement Office by the system.

 

　　Judging from the four batches and five rounds of national procurement practices, the National Medical Insurance Bureau has gradually formed a standardized and systematic process of national procurement.
There have been news in the industry that the fifth batch of national procurement will be completed before July 1.
Based on the timetable of the first four batches, some insiders predict that the fifth batch of national procurement may be officially released at the end of May or early June.
The program immediately starts the bid opening.

 

　　In January of this year, the General Office of the State Council formally issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs", which officially announced the normalized and institutionalized arrangements for centralized drug procurement.
From the perspective of the fifth batch of national procurement schedules, two batches of national procurement each year may become the norm.
In the future, it will gradually cover all kinds of clinically necessary and reliable drugs on the market in China, including Chinese patent medicines and biosimilars.
The price cuts are all-round.
Turn on.

 

　　The fifth batch of national procurement reports

 

　　(Note: Circulated in the industry, subject to official release)

　　Medical Network, April 16 News On April 15, the "Notice on Reporting the Purchasing Data of the Fifth Batch of National Organizations for Centralized Procurement of Drugs" circulated in the industry, which means that the fifth batch of national procurement officially kicked off.

 

　　According to the report volume catalogue, this time involves 60 varieties and as many as 207 product specifications.
It is by far the largest scale and the largest number of products, including omega-3 fish oil medium/long-chain fat emulsion injection, A Facalcitol oral constant-release dosage form, aripiprazole oral constant-release dosage form, azithromycin injection, esomeprazole (esomeprazole) injection, cefuroxime injection and other clinically commonly used varieties, as well as budi Three inhalants of acetonide, compound ipratropium bromide and ipratropium bromide, and special dosage forms such as moxifloxacin eye drops.
Some insiders predict that the market size that affects the terminal may exceed 50 billion yuan.

 

　　Injection up to 31 varieties , more than half

 

　　Injections have always been the main force in the hospital market.
According to data from Minai.
com, the sales of terminal chemical injections in China's public medical institutions reached 636.
9 billion yuan in 2019.
It can be found from the circulated fifth batch of reports that the focus of national centralized procurement is gradually tilting towards injections.
Among the 60 varieties involved in the reporting list, 31 are injections, azithromycin injection, cisatracurium besilate injection, iohexol injection, iodixanol injection, fluconazole sodium chloride injection, method Sudil injection, glycopyrrolate injection, cefuroxime injection and many other commonly used clinical injections are listed.

 

　　Taking the included esomeprazole sodium as an example, Minnet data shows that in 2019, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal treatment of peptic ulcer The size of the drug market exceeded 40 billion yuan, and the proportions of injection and oral administration were 58% and 42% respectively.
From the perspective of injection products, pantoprazole sodium for injection, esomeprazole sodium for injection (esomeprazole sodium), and lansoprazole for injection ranked in the top five.

 

　　Among them, the sales of esomeprazole sodium in 2019 exceeded 3 billion yuan, and the market share of the leading company AstraZeneca in the first half of 2020 was close to 50%.
Domestic pharmaceutical companies Zhongzhengda Tianqing Pharmaceutical Group and Jiangsu Osaikang Pharmaceutical The industry accounts for 29% and 13% respectively.
The price competition of related pharmaceutical companies may cause another change in the market competition pattern.

 

　　With the formal implementation of the injection consistency evaluation policy last year, the time for the over-evaluated injections to be included in the national procurement has been significantly shortened.
According to data analysis, as of the end of March, there are as many as 33 injection varieties that meet the requirements of the fifth batch of centralized procurement (original research + number of reviewers ≥ 3).
Compared with the pre-incorporated varieties, the National Medical Insurance Bureau should collect all of them.
The goal of mining is accelerating.

 

　　In the fourth batch of national centralized procurement, 8 injections including pantoprazole, ambroxol, and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 31 injections, the intensity of the price competition can be imagined.
After sorting out, it is found that the more competitive varieties include: rivaroxaban tablets with 13 over-rated companies, esomeprazole sodium for injection over-rated by 9 companies, and ofloxacin chlorinated with over-rated 6 companies Sodium injection, 5 reviewed ceftriaxone sodium for injection, ceftazidime for injection, etc.

 

　　April 19 or officially start reporting

 

　　According to the requirements of the document, the fifth batch of national-organized centralized drug pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement product range related procurement data will rely on the national-organized centralized drug procurement comprehensive service platform, and take the form of online reporting.

 

　　According to the arrangement, local medical insurance bureaus will guide and coordinate procurement agencies to complete the reporting work: before 24:00 on April 18, all provinces can conduct volume reporting operation tests through the system; volume reporting will be officially launched on April 19, and each province will select medical institutions directly or on behalf of the provincial newspaper reported that way, complete the relevant medicines pre-purchase amount, its Chinese medicine treatment direct reporting agency must be completed before at 4:00 on April 2 on the 30th; and in front at 17:00 on May 12, the provinces need to complete the pre-related drugs Procurement volume review work, summarized, exported and printed, stamped with the official seal of the Provincial Medical Insurance Bureau, and submitted the electronic files and scanned copies to the Joint Procurement Office by the system.

 

　　Judging from the four batches and five rounds of national procurement practices, the National Medical Insurance Bureau has gradually formed a standardized and systematic process of national procurement.
There have been news in the industry that the fifth batch of national procurement will be completed before July 1.
Based on the timetable of the first four batches, some insiders predict that the fifth batch of national procurement may be officially released at the end of May or early June.
The program immediately starts the bid opening.

 

　　In January of this year, the General Office of the State Council formally issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs", which officially announced the normalized and institutionalized arrangements for centralized drug procurement.
From the perspective of the fifth batch of national procurement schedules, two batches of national procurement each year may become the norm.
In the future, it will gradually cover all kinds of clinically necessary and reliable drugs on the market in China, including Chinese patent medicines and biosimilars.
The price cuts are all-round.
Turn on.

 

　　The fifth batch of national procurement reports

 

　　(Note: Circulated in the industry, subject to official release)